GlobeNewswire

Nasdaq Sees Continued Momentum in U.S. Listings with Record-Breaking Exchange Transfers and Improved IPO Environment

Dela

Record number of transfers valued at $379.8 billion market cap joining Nasdaq from NYSE in 2017

Leading U.S. exchange in total number of IPOs for 16 consecutive quarters

NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced today that it welcomed a total of 262 new listings so far in 2017 - including 133 initial public offerings (IPOs) and 33 transfers. The record-breaking year of exchange transfers is a validation of our long-term commitment to listed companies across all sectors at any stage of their growth journeys. Nasdaq has extended its IPO leadership to 16 consecutive quarters in the U.S. with a 62 percent win rate. Notable IPOs in 2017 included Roku, Redfin, CarGurus, National Vision, Denali and Hamilton Lane.    

This year, the total market value of all companies joining Nasdaq from the NYSE since 2005 has exceeded $1.2 trillion dollars. In 2017, Nasdaq welcomed a total of 33 switches, including 12 companies and 21 exchange traded products (ETPs), with a combined market value of approximately $379.8 billion. Company transfers included PepsiCo, Inc. ($165.8B market cap), Principal Financial Group ($20.6B market cap), Workday ($21.8B market cap), Brookfield Property Partners ($15.4B market cap), Xcel Energy ($25.7B market cap) and Visteon ($4B market cap). PepsiCo is the largest exchange switch to date.

Maintaining its position as the leading global listing venue, companies from a diverse range of industries and countries successfully launched their IPOs on Nasdaq in 2017, raising a total of approximately $15.1 billion. Nine of the top 10 best performing U.S. IPOs chose Nasdaq as their home exchange as well as 8 of the top 10 performing technology IPOs (as of the market close on December 15, 2017).


Nasdaq Weighted IPO Return 2017
Total IPOs 133 23.6 %
Tech IPOs 19 70.5 %

Major Indices
DOW   24.9 %
S&P 500   19.63 %
Nasdaq   29 %

Data source: Nasdaq, as of market close on December 15, 2017

"Since 1971, Nasdaq has supported many of the world's most innovative and admired companies and we couldn't be more proud to be the long-term partner throughout all stages of their journeys - before, during and after the IPO," said Nelson Griggs, President, Nasdaq Stock Exchange. "This year, we welcome the next generation of entrepreneurs and some of the most recognized global brands to the Nasdaq family, while celebrating milestones of Nasdaq listed companies including Amazon, Starbucks and Celgene. Their achievements are the cornerstone of our nation's economic growth, delivering breakthrough innovations in technology, medicine, entertainment and all areas that impact our daily life."

Companies celebrating their listing milestones include:

  • Amazon.com, Inc. (ticker: AMZN) - listed on May 16, 1997, celebrating its 20th listing anniversary. The stock opened at $18 per share in 1997 and is trading above $1,000 today.
  • Starbucks Corporation (ticker: SBUX) - listed on July 2, 1992, celebrating its 25th listing anniversary. Since its listing on Nasdaq, it grew from 165 stores to over 26,000 global locations.
  • Celgene Corp. (ticker: CELG) - listed on August 7, 1987, celebrating its 30th listing anniversary. There are more than 300 clinical trials at major medical centers using compounds from Celgene.
  • Netflix, Inc. (ticker: NFLX) - listed on May 23, 2002, celebrating 15th listing anniversary. Founded in 1997, Netflix was a video mailing service. Today Netflix reaches 100 million subscribers globally and transforms the entertainment industry with its original content.
 
 
2017 Total New Listings* 262
Initial Public Offerings** 133
Other Listings 56
ETPs (including ETP transfers) 61
Company Transfers to Nasdaq from Competing Exchanges*** 12

*Data source: Nasdaq, FactSet, EDGAR Online, January 1, 2017 - December 15, 2017
**Includes the following capital raising events in the U.S. as priced in 2017: IPO, REIT, SPAC, BDC, Foreign Exchange Dual Listing, Best Effort and Spin-offs
***Includes all transfers announced as of December 19, 2017

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company's public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com.

Media Relations Contact:

+  Stephanie Lowenthal
+  (646) 441-5073
Stephanie.Lowenthal@nasdaq.com
+  Emily Pan
+  (646) 441-5120 
emily.pan@nasdaq.com

- NDAQG -




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum